SUMMARY Infusion of small amounts of blood plasma into isolated, isovolumk rabbit hearts perfused with Tyrode's solution resulted In coronary vasoconstriction followed by a decrease in left ventricular developed pressure and dP/dt. Maximal effects were obtained with a perfosate plasma concentration of 1%. Increasing the plasma concentration beyond 1% did not appreciably increase toe coronary vasoconstriction. During perfuskM with 2% plaaaut, the coronary flow-oxygen uptake ratio was unchanged over a range of perfusion pressures (40-100 mm Hg) and vascular resistance increased with pressure. In the absence of plasma, the coronary flow-oxygen uptake ratio increased with pressure and vascular resistance decreased. Thus, cardiac regulation of coronary flow ia response to changes in perfusion pressure occurred in the presence of plasma but not in its absence. The effects of plasma were reduced with two different inhibitors of prostaglandin synthesis (5,9,11,14-eicosatetraynolc acid and indometfaacin). At a perfusate concentration of 50 /ig/ml, indomethadn abolished the effects of 2% plasma. Rat stomach strip bioassay for prostaglaadin activity indicated that the vasoconstrictor effect of plasma was accompanied by a 4-fold increase in the release of prostaglandin activity by the isolated hearts. The vasoconstrictor effect of plasma also was accompanied by an Increase in the conversion of 'H-arachidonate to radiolabeled prostaglandins E, and F*,. These results indicate that a relationship exists between a coronary vasoconstrictor in plasma, cardiac prostaglandin synthesis, and the regulation of coronary flow in response to changes in perfmsion pressure in isolated rabbit hearts.
that regulation in response to changes in perfusion pressure occurs during blood perfusion, but not during perfusion with a physiologic salt solution.
To explore this question further, we studied the action of blood plasma on the coronary vasculature and examined its role in the regulation of coronary flow in response to changes in perfusion pressure in isolated isovolumic rabbit hearts. The results of these experiments led to an investigation of the relationship between the action of plasma and cardiac prostaglandin production.
Methods

ISOVOLUMIC ISOLATED HEART PREPARATION
Hearts were excised from New Zealand white male rabbits (2-3.5 kg) which received intravenous injections of sodium pentobarbital (45 mg/kg) for anesthesia and heparin (200 U/kg). Each excised heart was placed in cold (0°C) Tyrode's solution, the aorta was cannulated, and the heart then was attached by the cannula to a perfusion manifold. Care was taken to exclude air from the heart and cannula. Pressure and temperature of the perfusate were monitored through fittings in the perfusion manifold. We used an automatic infusion pump to infuse test solutions into the perfusate through additional fittings in the manifold.
A drain with an inside diameter (i. The hearts were perfused with either Tyrode's solution (saturated with 95% O,-5% CO,, pH 7.4, 37°C) or Tyrode's solution containing plasma preparations. Perfusion pressure was controlled by regulating the pressure of the O,-CO, gas phase in the perfusate reservoirs. The isolated hearts were maintained at 37°C in a humidified chamber.
OXYGEN UPTAKE
Oxygen tension (Po,) was measured at 37°C with a dual-probe polarographic oxygen monitor incorporating flow-through oxygen-monitoring cells. One probe sampled the perfusate as it entered the aorta, the other probe monitored the Po, of the coronary effluent. Oxygen consumption was calculated from the difference in Po, between inflow and outflow.
BLOOD PREPARATIONS
Venous and arterial rabbit plasma was prepared at room temperature by centrifugation of blood drawn from the inferior vena cava or the left ventricle of heart donors just prior to excision of the heart. Plasma either was used immediately or was stored by freezing at -20°C. Venous and arterial preparations produced similar results in all experiments. Lipid-deficient plasma protein (LDP) was prepared by a method which removed over 98% of the lipids.' Plasma (10 ml, 5°C) was mixed for 2 hours at -20°C with 240 ml of precooled (-20°C) ethanol-diethyl ether (3:1). The precipitated proteins were collected by filtration, washed with ether (-20°C), then scraped into 300 ml of precooled ether and stirred overnight at -20°C. The protein precipitate again was filtered and washed, then dried for 2 hours in vacuo in the presence of paraffin shavings to remove ether traces. The LDP preparations were stored at 5°C, then dissolved in Tyrode's solution before use.
CHEMICALS
The lipids used were: tritium-labeled arachidonic acid (5,6,8,9,11,12,14,15-'H), 72 Ci/mmol (New England Nuclear); unlabeled arachidonic acid (Sigma); prostaglandins (Upjohn) (prostaglandins E,, E,, F l a as acids, prostaglandin F,,, as the tromethamine salt); and 5,8,11,14-eicosatetraynoic acid (TYA) (Hoffman-LaRoche). These fatty acids were dissolved in a small amount of 0.5 M NaHCO,, then diluted with 0.5% rabbit albumin (Cohn fraction V, ICN Pharmaceuticals) in Tyrode's solution. The 0.5% albumin solution was used because both saturated and unsaturated fatty acids can have depressant effects on isolated hearts unless first bound to albumin.
10 Indomethacin (Sigma) was dissolved in 95% ethanol (12 mg/ml). Atropine (Sigma) was dissolved in Tyrode's solution (1 mg/ml). These stock solutions were prepared daily, and diluted with Tyrode's solution just prior to use.
BIOASSAY OF PROSTAGLANDIN ACTIVITY
Prostaglandin activity was estimated using a modification of a bioassay that employs longitudinal strips of rat stomach." The strips were superfused at 2 ml/min with Tyrode's solution (95% O,-5% CO, saturation, pH 7.4, 37°C) containing atropine, 10"'M, and indomethacin, 1.5 x 10"' M. 1 Prostaglandin activity was studied in 2-ml portions of coronary effluent which were brought to 37°C and equilibrated with 95% O,-5% CO,. The superfusate was interrupted and the test solution was superfused over the muscle. The response elicited was compared to that produced by standard doses of prostaglandin E,. 
EXTRACTION AND MEASUREMENT OF RADIOLABELED PROSTAGLANDINS
Results
EFFECT OF PLASMA ON CORONARY FLOW AND MYOCARDIAL ACTIVITY
Hearts were perfused with Tyrode's solution until coronary flow, left ventricular developed pressure, and heart rate reached steady values. Plasma then was added to Tyrode's solution and infused at a constant rate. Within 1 minute coronary flow declined and this was followed by decreases in developed pressure and dP/dt (Fig. 1) . In about 2 minutes, low levels were reached which persisted until the plasma infusion was stopped. Flow and pressure values returned to their original levels in 5-6 minutes. Repeated observations could therefore be made on the same heart, and each heart could act as its own control.
The effect of plasma was dose-dependent up to a perfusate concentration of about 1%. Only slightly greater effects were observed at higher concentrations (Fig. 2) . Coronary flow was decreased by 65% with 1% plasma. The viscosity of 1% plasma, calculated from the data of Merrill" or from our measurements using a capillary viscometer, accounts for less than 1% of the decrease in flow. Thus, the decreases in coronary flow must have been due to an increase in vascular resistance.
Coronary flow decreased before contractions weakened ( Fig. 1) , suggesting a primary effect on the coronary vasculature. Since maximal effects were obtained with such low levels of plasma, the substance responsible for vasoconstriction must be present in excess in circulating blood. Moderate or even large fluctuations in its blood concentration should have little effect on coronary flow. 
EFFECT OF PLASMA ON REGULATION OF CORONARY FLOW
In these experiments, hearts were perfused alternately with either Tyrode's solution or 2% plasma in Tyrode's solution. The perfusion pressure was increased, in increments of 20 mm Hg, from 40 mm Hg to 100 mm Hg. When hearts were perfused with 2% plasma, increases in perfusion pressure caused moderate increases in coronary flow and oxygen uptake ( Fig. 3A and B ), but the coronary flow-oxygen uptake ratio remained unchanged ( Fig. 3C ) and vascular resistance increased (Fig. 3D) . In contrast, when perfused with only Tyrode's solution, increases in perfusion pressure caused disproportionate increases in coronary flow (Fig.  3A) . The coronary flow-oxygen uptake ratios increased ( Percent plasma in perfusate 3C) while vascular resistance declined (Fig. 3D) . Hence, the hearts regulated their coronary flow in response to increases in perfusion pressure in the presence of plasma but not in its absence.
The increase in vascular resistance observed in the presence of plasma must have been due to coronary vasoconstriction in response to pressure. Plasma could supply a substance which is essential for this response but which is not contained within the heart. Since blood causes contraction in isolated rat stomach strips" as well as arterial strips,' and since prostaglandins cause contraction in rat stomach strips" and are vasoactive, 17 we explored the possibility of a relationship between plasma and prostaglandins in isolated rabbit hearts. Initially, the effects of inhibitors of prostaglandin synthesis on the action of plasma were examined. To decrease the possibility of nonspecific effects, two structurally different inhibitors were employed, indomethacin and 5,8,11,14-eicosatetraynoic acid (TYA)."
EFFECT OF INHIBITORS OF PROSTAGLANDIN SYNTHESIS
Hearts were perfused alternately with either Tyrode's solution or 2% plasma in Tyrode's solution. The perfusion pressure was maintained at 60 mm Hg while indomethacin or TYA was infused into the perfusate. Equimolar concentrations of these inhibitors produced similar results; those obtained with indomethacin are summarized in Figure 4 . Either in the presence or absence of plasma, these inhibitors caused an increase in flow rate and the flow rate-oxygen uptake ratios. The dose-response curves for the ratios paralleled those for coronary flow. Hence, the increase in coronary flow was in excess of that required to maintain the oxygen supply. Much higher concentrations of both inhibitors were required to produce an effect in the presence of plasma. However, high inhibitor concentrations abolished the vasoconstrictor effect of plasma; when the perfusate concentration of indomethacin was 50 fzg/ml, the infusion of plasma did not result in a decrease in coronary flow. These results suggest a relationship between the action of plasma and cardiac prostaglandin synthesis. They also suggest a possible mechanism. More indomethacin is required to inhibit prostaglandin synthesis in the presence of high substrate levels than when low levels are employed." Since more indomethacin or TYA was required to produce coronary vasodilation in the presence of plasma, perhaps plasma acts by providing a precursor or cofactor for cardiac prostaglandin synthesis.
This possibility first was examined in studies on rat stomach strips, in which both blood " and arachidonate 10 cause contractions. The strips were prepared as described herein for the prostaglandin bioassay except that indomethacin initially was omitted from the superfusate. Indomethacin was added as indicated in Table 1 . Plasma and arachidonate both caused the strips to contract. Indomethacin inhibited the effects of both plasma and arachidonate. When the concentration of arachidonate was increased, more indomethacin was required to abolish the contraction (Table  1) . When precursors of prostaglandin synthesis, such as arachidonate, were removed from plasma by extraction of the plasma lipids, the lipid-deficient plasma protein (LDP) retained only about 5% of the original activity (Table 2) .
These results are in accord with the supposition that plasma might act by providing a precursor for prostaglandin synthesis. However, when arachidonate and preparations of LDP were tested in isolated rabbit hearts, unexpected results were obtained. The coronary vasoconstrictor activity of LDP preparations was compared to that of plasma by using the initial slope of the dose-response curve (Fig. 2) as the basis for an assay. Each LDP preparation was dissolved in Tyrode's solution to give a protein concentration equal to that of the original plasma. When infused into isolated hearts, the LDP preparations were found to retain most of the vasoconstrictor activity (Table 3) . One LDP preparation had only 42% of the original activity but all others retained more than 80%. When arachidonate (1-5 ug/m\ of perfusate) was infused into isolated rabbit hearts for periods of up to 10 minutes, it had no effect on coronary flow, either in the presence or absence of the coronary vasoconstrictor in plasma.
These results show that the vasoconstrictor is neither arachidonate nor the blood component which causes contraction of the rat stomach strips. However, the vasoconstrictor effect of LDP could be inhibited with indomethacin; the greater the vasoconstrictor activity of the LDP preparation, the more indomethacin required for inhibition (Fig.  5A) . Thus, the results are consistent with the suggestion that a relationship between the coronary vasoconstrictor and cardiac prostaglandin synthesis does exist. This possi- Indomethacin: /jg/ml bility was explored further by assessing the release of biological activity and the formation of radiolabeled prostaglandins by isolated hearts.
SYNTHESIS AND RELEASE OF PROSTAGLANDINS BY ISOLATED HEARTS
Because the LDP preparations had little prostaglandin activity when tested on the rat stomach strip system, this system could be employed to assay the coronary effluent of LDP-perfused hearts for biological activity. Indomethacin (1.5 x lO" 5 M) added to the supcrfusate inhibited the residual prostaglandin-likc activity of the LDP preparations. Samples of coronary effluent were collected from hearts which were perfused alternately with either Tyrode's solution or LDP (0.6 mg/ml) in Tyrode's solution. In all hearts tested, the decrease in flow caused by LDP was accompanied by an increase in release of prostaglandin activity (Table 3) . Infusion of indomethacin into the perfusates caused a dose-dependent reduction in the release of this activity (Fig. 5B) . However, the greater the vasoconstrictor activity of the LDP preparation, the more indomethacin was required for inhibition. Thus, the coronary vasoconstrictor not only stimulated the release of prostaglandin activity but it antagonized the effects of indomethacin. Cardiac synthesis of prostaglandins was evaluated further by infusing *H-arachidonate into hearts and analyzing the coronary effluent for 'H-labeled prostaglandins with the aid of thin layer chromatography. Radioactivity was recovered from the regions of the chromatograms containing prostaglandins E and F (Table 4) . Perfusion with LDP increased the amount of label recovered from both these regions. Since prostaglandins E, and F f c are formed from arachidonate, 11 these data show that the coronary vasoconstrictor stimulated the synthesis of both these prostaglandins.
The effects of exogenous prostaglandins on coronary flow in isolated hearts also was examined. The prostaglandins first were bound to albumin to reduce the possibility of nonspecific depressant effects. 10 The prostaglandins were infused at rates which produced concentrations from 0.1 ng/ml to 5.0 Mg/ml. Prostaglandins E,, E,, F,,,, and F^ had no effect in concentrations up to 50 ng/ml. In high concentrations (0.5-5.0 /*g/ml) prostaglandins E, and E, caused an increase in coronary flow, whereas prostaglandins F, n and F*, caused a decrease in flow. These effects were Contractions of rat stomach strips produced by tew samplet were compared with those caused by standard amounts of prostaglandin E, (PGE,). See text for additional experimental details.
observed both in the presence and absence of the coronary vasoconstrictor.
Discussion
When a vascular system is unregulated its resistance to flow decreases with increasing transmural pressure due to passive distention of the vessels.
12 -" When the isolated rabbit hearts were perfused with Tyrode's solution, an increase in perfusion pressure caused a decrease in vascular resistance. This change could not have been due to an in- (Table 3) .
crease in myocardial oxygen uptake because the coronary flow-oxygen uptake ratio increased markedly in the absence of plasma. During perfusion with 2% plasma, the vascular resistance increased as a function of pressure and thus attenuated the increase in flow. The increase in flow, in the presence of plasma, was just enough to meet the additional oxygen requirements ( Fig. 3A and C) . Therefore, cardiac regulation of coronary flow in response to changes in pressure was good in the presence of plasma, but inadequate in its absence. This indicates that there must be a component of plasma, a coronary vasoconstrictor, that is essential for the regulation of coronary flow by isolated rabbit hearts in response to changes in perfusion pressure.
Our results suggest a relationship between the action of the coronary vasoconstrictor and prostaglandin synthesis. The vasoconstrictor stimulates the synthesis by the isolated hearts of prostaglandins E| and F», from 'H-arachidonate. This synthesis is accompanied by the release of biological activity that is inhibited by either indomethacin or TYA. Furthermore, a concentration-dependent antagonism between the coronary vasoconstrictor and both prostaglandin synthetase inhibitors was seen. Block et al. 1 found that anoxia blocked the release of prostaglandin-like activity and produced an increase in coronary flow in isolated rabbit hearts. These investigators failed to find an effect of indomethacin (1-2 jjg/ml) on the basal coronary flow rate. However, we found that the increase in flow produced by an Two Uptd-deficicnt pbuma protein (LDP) preparations were tested on two hearts. Repeated observations (n -6) were made on each heart. The perfusate was alternated between Tyrode's solution and Tyrode's solution plus LDP (0.6 mg/ml). A dose of 2 x 10* counts/min of 'H-»rachidonate was infused over a 30-second interval for each test. The coronary effluent was collected during infusion of the 'H-arachidonate and for 30 seconds thereafter.
indomcthacin concentration of 2 /ig/ml occurs so slowly that it is difficult to discern, even in the absence of plasma.
Since our results and those of others '-14 indicate that hearts synthesize prostaglandins continuously, it is tempting to speculate that this synthesis aids in the maintenance of coronary vascular tone. Our data indicate that the degree of vasoconstriction is directly proportional to the rate of prostaglandin synthesis. This is of interest because molecular (gaseous) oxygen is required in the synthesis of prostaglandins." If oxygen were rate-limiting, then a decrease in oxygen supply would result in a decrease in prostaglandin synthesis and an increase in coronary flow. In this regard, the venous Po, [as reflected in the coronary flow-oxygen uptake ratios (Fig. 3C) ] was constant during perfusion with plasma or LDP; but in their absence, or when their effects were inhibited with either indomethacin or TY A, the venous Po, not only increased markedly but varied considerably.
Although our data are consistent with the supposition that cardiac prostaglandin synthesis plays a central role in the regulation of coronary blood flow, they do not eliminate other possibilities. The impressive evidence"-" showing a relationship between coronary vasodilation and adenosine in the local regulation of coronary flow must be considered. Furthermore, there are some inconsistencies between our results and those of others. Needleman et al. B reported that bradykinin caused a transient decrease in vascular resistance accompanied by an increase in release of prostaglandins of the E type in isolated rabbit hearts perfused with KrebsHenseleit medium. Indomethacin (0.3 /ig/ml) inhibited both the increase in flow and the release of prostaglandin activity.* Kalsner" found that indomethacin, aspirin, or TYA induced contractions of isolated bovine coronary arterial strips while concurrently decreasing the production of E-type prostaglandins. In studies on isolated, blood-perfused, canine heart-lung preparations, Alexander et al." found that indomethacin (3.5 tig/m\) reduced both reactive hyperemia and cardiac prostaglandin E, production, but had no effect on adenosine-induced coronary vasodilation. Hence, under various conditions, coronary vasodilation may be accompanied by a decrease, an increase, or no change in the release of prostaglandins of the E type. Our data show that plasma-induced coronary vasoconstriction is accompanied by an increased synthesis of both prostaglandins E, and F*,. Perhaps coronary vasoconstriction is related to the synthesis of prostaglandins other than E type. In high concentrations, prostaglandins F,,, and F*. did cause coronary vasoconstriction, whereas prostaglandins E, and E, caused vasodilation.
Exogenous prostaglandins were without effect in amounts equivalent to 1 to 10 times the prostaglandin activity found in the coronary effluent. When administered in similar doses, prostaglandin E, was without effect on isolated rabbit hearts perfused with Krebs-Ringer solution.' The inactivity of prostaglandins at these concentrations docs not exclude involvement of cardiac prostaglandin synthesis in coronary vasconstriction or regulation of coronary flow. Both prostaglandin E, and F», are released by platelets during aggregation." Neither of these induces aggregation, but the endoperoxide prostaglandin G, does. 10 This labile prostaglandin formerly was considered only as an intermediate in the synthesis of prostaglandins E, and F*,. Evidence also has been presented which suggests that the rabbit aorta-contracting substance is a prostaglandin intermediate. 10 Hence, such an intermediate could be responsible for the coronary vasoconstriction that we observed.
Our results could provide an explanation for some of the conflicting reports by others'-*• 14 -"• " concerning the involvement of prostaglandins in the regulation of coronary flow. Experiments on isolated hearts perfused with solutions that did not contain blood or plasma usually produced high coronary flow rates.'- 5 We have found prostaglandin synthesis to be minimal under these conditions and regulation of coronary flow, at least in response to changes in perfusion pressure, to be impaired. In experiments on blood-perfused hearts 14 -"• " the amount of prostaglandin synthetase inhibitor used may have been insufficient. Our data indicate that inhibition by indomethacin or TYA is dependent on the relative concentrations of inhibitor and plasma. Indomethacin concentrations of about 20 jtg/ml were required to produce a significant effect in the presence of 2% plasma. Assuming a linear relationship, concentrations of about 1 mg/ml would be needed to produce a direct effect in hearts perfused with whole blood. This is in excess of the amounts employed in experiments with-blood-perfuscd hearts.* 4 -"• "
